- Home
- ACIU vs TCRX Comparison
ACIU vs TCRX Comparison
Compare ACIU & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TCRX
- Stock Information
- Founded
- ACIU 2003
- TCRX 2018
- Country
- ACIU Switzerland
- TCRX United States
- Employees
- ACIU N/A
- TCRX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- TCRX Health Care
- Exchange
- ACIU Nasdaq
- TCRX Nasdaq
- Market Cap
- ACIU 305.7M
- TCRX 257.5M
- IPO Year
- ACIU 2016
- TCRX 2021
- Fundamental
- Price
- ACIU $3.23
- TCRX $3.95
- Analyst Decision
- ACIU Strong Buy
- TCRX Strong Buy
- Analyst Count
- ACIU 2
- TCRX 5
- Target Price
- ACIU $12.00
- TCRX $11.40
- AVG Volume (30 Days)
- ACIU 131.4K
- TCRX 260.3K
- Earning Date
- ACIU 11-05-2024
- TCRX 11-12-2024
- Dividend Yield
- ACIU N/A
- TCRX N/A
- EPS Growth
- ACIU N/A
- TCRX N/A
- EPS
- ACIU N/A
- TCRX N/A
- Revenue
- ACIU $48,505,404.00
- TCRX $9,362,000.00
- Revenue This Year
- ACIU N/A
- TCRX N/A
- Revenue Next Year
- ACIU $938.44
- TCRX $3.10
- P/E Ratio
- ACIU N/A
- TCRX N/A
- Revenue Growth
- ACIU 4097200.00
- TCRX N/A
- 52 Week Low
- ACIU $2.25
- TCRX $3.73
- 52 Week High
- ACIU $5.14
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ACIU 54.88
- TCRX 31.07
- Support Level
- ACIU $3.11
- TCRX $4.03
- Resistance Level
- ACIU $3.41
- TCRX $6.23
- Average True Range (ATR)
- ACIU 0.23
- TCRX 0.39
- MACD
- ACIU 0.03
- TCRX -0.13
- Stochastic Oscillator
- ACIU 46.72
- TCRX 4.33
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.